Vitiligo
BOOK A CONSULTATIONWhat is vitiligo and what causes it?
- Autoimmune skin condition
- Loss of melanocytes causing white patches
- Affects all skin types and ethnicities
- Accurate diagnosis essential
Vitiligo is an autoimmune skin condition in which the immune system mistakenly targets and destroys the melanocytes, the pigment-producing cells that give skin its colour, resulting in well-defined, milky white patches caused by the localised loss of melanin. It can affect any part of the body, including the face, hands, trunk, and genitalia, and can also depigment the hair and mucous membranes. It affects roughly one to two percent of the population across all ethnicities, though its visual impact is more pronounced in darker skin tones.
The underlying mechanism involves a breakdown in immune self-tolerance, in which autoreactive T lymphocytes destroy melanocytes. Research has identified the JAK-STAT signalling pathway as a central driver of this immune attack, with important treatment implications, as JAK inhibitors that block this pathway restore pigmentation in active vitiligo. Vitiligo is strongly associated with other autoimmune conditions, particularly thyroid disease, so assessment for these is part of the initial evaluation.
Vitiligo is classified into subtypes with important implications for prognosis and treatment. Non-segmental vitiligo, the most common form, causes bilateral, often symmetrically distributed patches that tend to progress over time. Segmental vitiligo affects one segment in a unilateral, dermatomal pattern, tends to progress rapidly early then stabilises, and is less commonly associated with systemic autoimmunity. Universal vitiligo describes depigmentation affecting more than eighty percent of the body surface.
A critical point frequently underappreciated is that vitiligo can be misdiagnosed, as other conditions can cause loss of pigmentation, including pityriasis versicolor, post-inflammatory hypopigmentation, lichen sclerosus, naevus depigmentosus, idiopathic guttate hypomelanosis, and hypopigmented mycosis fungoides. Accurate diagnosis by a Consultant Dermatologist, supported by Wood's lamp examination, dermoscopy, and biopsy where needed, is therefore essential before any treatment.
What are my treatment options for vitiligo?
- JAK inhibitors - a major advance
- Topical anti inflammatory treatments
- Phototherapy (NB-UVB)
- Associated autoimmune conditions assessed
- Camouflage and psychological support where needed
Vitiligo is a treatable condition, and the treatment landscape has been transformed in recent years by JAK inhibitor therapies that can produce substantial, meaningful repigmentation in a significant proportion of patients. Treatment is selected according to the extent and activity of the disease, the patient's skin type, and their goals.
For localised or active vitiligo, first-line treatment typically involves topical anti-inflammatory agents. Topical calcineurin inhibitors such as tacrolimus and pimecrolimus are preferred for facial and sensitive-area vitiligo, suppressing the local autoimmune attack without the skin-thinning risk of topical corticosteroids, which remain an option for body vitiligo. Topical ruxolitinib, a JAK inhibitor in cream form, is an important newer addition that has demonstrated significant repigmentation in clinical trials, particularly for facial vitiligo.
Narrowband ultraviolet B (NB-UVB) phototherapy is one of the most established and effective treatments for generalised vitiligo, suppressing the immune attack on melanocytes and stimulating residual melanocyte activity to promote repigmentation. It is most effective for non-segmental vitiligo, particularly the face and trunk, and is typically administered two to three times per week, with the best responses usually seen at twelve months.
The most significant development in recent years is the advent of oral JAK inhibitors, which target the JAK-STAT pathway central to the autoimmune destruction of melanocytes. Clinical trials have shown they can produce clinically meaningful repigmentation in active non-segmental vitiligo, including in areas depigmented for many years, and can halt the spread of active disease. They require specialist prescribing, careful patient selection, and monitoring, and access in a private specialist setting avoids the waiting times and formulary restrictions of NHS pathways.
For a small number of patients with very extensive vitiligo for whom repigmentation is no longer realistic, depigmentation may be considered, using topical agents to remove the remaining pigment from unaffected skin to create a uniform skin tone.
Supportive measures also form an important part of management. Skin camouflage products can make a significant difference to confidence and quality of life while repigmentation is underway, and sun protection is essential at all stages, as the absence of melanin makes depigmented skin highly vulnerable to sunburn. Where the psychological impact is significant, Dr Ophelia can facilitate referral for psychological support including CBT, and assessment for associated autoimmune conditions, particularly thyroid dysfunction, is performed with blood tests for every patient.
Why should I see Dr Ophelia Veraitch for vitiligo treatment in London?
- Award winning consultant dermatologist. Accurate diagnosis and full treatment spectrum
- JAK inhibitor prescribing expertise.
- Access to the newest and most effective vitiligo treatments
- Specialist in darker skin tones
- Experienced in vitiligo across all ethnicities
- Holistic, patient centred care. Psychological impact addressed alongside medical treatment
With vitiligo, the quality of diagnosis and access to treatment makes a substantial difference to outcomes. As a Consultant Dermatologist in independent private practice, Dr Ophelia Veraitch uses Wood's lamp examination, dermoscopy, and skin biopsy where needed to confirm the diagnosis and classify the subtype accurately, and has the prescribing authority to offer the complete range of treatments, including oral and topical JAK inhibitors, without the restrictions and waiting times of NHS settings.
She has extensive experience treating vitiligo across all skin tones and ethnicities, with particular depth of understanding of its impact in darker skin types. She understands that vitiligo is far more than a cosmetic condition, and her approach addresses the psychological dimensions alongside the medical treatment, with the honesty and realistic expectation-setting that every patient deserves.
HELP
Frequently Asked Questions - Vitiligo Treatment
No. Albinism is a genetic condition present from birth in which the body produces little or no melanin across the skin, hair, and eyes, whereas vitiligo is an acquired autoimmune condition that develops during life, destroying melanocytes to produce discrete patches of depigmentation against normal skin.
Yes, more commonly than many realise, as several conditions including pityriasis versicolor, post-inflammatory hypopigmentation, lichen sclerosus, and rarely hypopigmented mycosis fungoides can resemble it. Accurate diagnosis using Wood's lamp examination, dermoscopy, and biopsy where needed is therefore essential.
Non-segmental vitiligo, the most common form, causes bilateral, often symmetrical patches, is progressive, and is strongly associated with other autoimmune diseases including thyroid disorders. Segmental vitiligo affects one area in a unilateral, dermatomal pattern and tends to progress rapidly early then stabilise.
JAK inhibitors block the Janus kinase signalling pathway central to the autoimmune attack on melanocytes, halting their destruction and allowing residual melanocytes to reactivate and repigment. Both oral and topical JAK inhibitors have demonstrated clinically significant repigmentation in active non-segmental vitiligo, including in areas depigmented for years.
Yes; vitiligo carries an increased risk of other autoimmune disorders, most commonly thyroid disease including Hashimoto's thyroiditis and Graves' disease, as well as alopecia areata, type 1 diabetes, pernicious anaemia, and inflammatory bowel disease. Dr Ophelia screens for these with blood tests for every patient.
Yes, particularly in non-segmental vitiligo, which can produce new depigmentation over time at an unpredictable rate. Koebnerisation, in which new vitiligo develops at sites of skin trauma or friction, is a recognised feature of active disease, and prompt treatment aims to prevent further spread.
Vitiligo affects all skin types with similar prevalence, but its visual impact is considerably more pronounced in darker skin tones where the contrast is much greater, making it more psychologically distressing and socially visible, particularly for patients of South Asian, East Asian, African, Afro-Caribbean, and Middle Eastern heritage.
Yes, though the likelihood decreases as depigmentation persists because melanocyte reservoirs may be depleted. However, clinical trials of JAK inhibitors have demonstrated meaningful repigmentation even in long-standing patches, and the face and hair-bearing areas tend to respond better than acral areas such as the hands and feet.
Vitiligo treatment requires patience: topical treatments typically need three to six months before visible improvement, NB-UVB phototherapy usually at least twelve months, and JAK inhibitors have demonstrated responses within a few months, though sustained treatment is required to maintain the response.
Because the absence of melanin leaves depigmented skin with no natural protection against UV, a broad-spectrum SPF 50 sunscreen should be applied daily to all depigmented areas, with protective clothing and shade-seeking. Paradoxically, carefully controlled UV as NB-UVB phototherapy is a recognised treatment under medical supervision, unlike unprotected sun exposure.
Vitiligo requires accurate diagnosis, assessment for associated autoimmune conditions, and access to the full range of treatments including JAK inhibitors, which only a qualified medical practitioner with specialist dermatological expertise can prescribe. A GP can provide basic assessment and refer for phototherapy but cannot classify the subtype or prescribe JAK inhibitors, and aesthetic practitioners cannot diagnose or prescribe at all.